Kythera Biopharmaceuticals, Inc. of Calabasas has successfully completed two Phase 2 clinical studies of its lead product candidate, ATX-101, which is meant to reduce ‘under-the-chin,’ or submental, fat. There were 157 patients in the double-blind studies conducted in 10 centers in the United Kingdom, Canada, and Australia. The privately-held company has two other products in development as well, to address pigmentation modulation and dermal contouring.